Patent number: 6369193
Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.
Type:
Grant
Filed:
October 19, 1999
Date of Patent:
April 9, 2002
Assignees:
University of Utah Research Foundation, The Salk Institute for Biological Studies
Inventors:
A. Grey Craig, David Griffen, Baldomero M. Olivera, Maren Watkins, David R. Hillyard, Julita Imperial, Lourdes J. Cruz